Clarify the investment story
Investors should quickly understand the platform, the two development programs, the clinical track record and where to find the current facts supporting the story.
Post-merger public-company website
Give precision neurostimulation a website built for its next chapter.
A modern website for Cortigent Holdings, Inc. that helps investors, patients, clinicians and partners understand the technology, development programs, clinical progress and public-company information in one visit.
cortigent
Nasdaq: CRGT
Precision neurostimulation designed to help recover sight and motor function.
One understandable story connects the technology platform, Orion®, the Stroke Recovery System, clinical progress and investor information.
TechnologyPrecision Neurostimulation Platform
Lead ProgramOrion® Artificial Vision
Development ProgramStroke Recovery System
Public CompanyInvestor Relations + QuoteMedia
Technology • Programs • Clinical & Research • InvestorsExplore Cortigent →
Executive Summary
This is more than a redesign.
The current website explains important parts of Cortigent's science, but it was built for a wholly owned subsidiary. The post-merger site must introduce Cortigent Holdings, Inc. as a Nasdaq-listed neurotechnology company while keeping the technology, clinical and patient story understandable.
Clearly explain the technology
The site should make precision neurostimulation understandable without oversimplifying the medical device, clinical or regulatory realities.
Let IBN carry the work
IBN will lead the research, strategic organization, writing, migration, design and development while limiting Cortigent's involvement to essential access, answers and review.
Strategic Direction
Build the website around Cortigent’s strongest story.
The new website should make Cortigent’s precision neurostimulation platform, development programs, clinical progress and technology legacy easy to understand while giving investors direct access to the public-company information they expect.
Strong raw material, subsidiary-era structure
The current site explains Orion, the Stroke Recovery System and the underlying technology, but visitors still have to assemble the broader company story.
- Vivani subsidiary and corporate-parent language becomes obsolete after the merger.
- Investor Relations is secondary rather than a primary website destination.
- The current Pipeline page contains stale clinical language and does not clearly separate current development from legacy technology.
- Press releases and public-company information are not presented through one automated Cortigent system.
- Leadership, governance, filing history and legacy ClearOne obligations require post-closing reconciliation.
One post-merger company story with evidence underneath
The redesigned site will make Cortigent's mission, technology, programs, clinical progress and public-company information work together.
- Introduce Cortigent Holdings, Inc. and Nasdaq: CRGT immediately.
- Organize the story as one platform supporting two development programs.
- Turn Investor Relations into a high-value destination with automated QuoteMedia content.
- Present Argus II only as historical technology and clinical experience—not as a current product.
- Build clear paths for investors, patients, clinicians, researchers and partners.
Planning references include Cortigent's current website, the merger announcement and the related Form 8-K.
Post-Merger Positioning
Present Cortigent as the focused neurotechnology company it has become.
The website should introduce the corporate identity first, then progressively reveal the technology, development programs, clinical evidence and patient impact that support the story.
Recommended Homepage Positioning
Precision neurostimulation designed to help restore critical body functions.
Cortigent Holdings, Inc. is a Nasdaq-listed neurotechnology company developing brain-interface medical devices for artificial vision and post-stroke motor recovery.
This is example positioning. IBN will refine the final wording during development using the latest approved disclosures and regulatory review.
Platform ClarityShow how the implant, wearable processing and targeted stimulation work together.
Program FocusKeep Orion and the Stroke Recovery System distinct but visibly connected.
Clinical EvidencePresent approved development milestones and results in a scannable format.
Investor AccessPut filings, releases, stock information, governance and contacts within easy reach.
Technology and Programs Architecture
One platform. Two development programs.
A simple architecture will help normal visitors understand the company without forcing them to interpret a traditional pharmaceutical-style pipeline. “Programs” is the recommended navigation label; “Product Development Pipeline” can appear where technically appropriate.
01
Precision Neurostimulation Platform
Proprietary microelectronics, a 60-electrode cortical surface array, wireless communication, wearable processing, software and neuroscience expertise form the core platform.
Core Technology02
Orion®
The lead investigational visual cortical prosthesis program is designed to deliver meaningful visual perception to people with profound blindness.
Lead Program03
Stroke Recovery System
A development-stage system intended to apply cortical stimulation to improve recovery of arm and hand movement after paralysis due to stroke.
Development ProgramExample from Another Public Company
A visual structure can make connected programs clear at a glance.
This reference shows the type of hierarchy IBN can adapt to distinguish the platform, Orion and the Stroke Recovery System.
How this translates: one central platform can feed two clearly differentiated development programs.Cortigent's final labels and facts will use approved disclosures.
Core Platform
Precision Neurostimulation
Neuroscience + microelectronics + software
Implant60-electrode cortical surface array
WirelessPower and data transmission
ProcessingWearable real-time processing
TargetingVisual or motor cortex
Existing Technology Assets
Reuse what works. Propose optional enhancements.
Cortigent already has useful device imagery, brain/cortex graphics, Orion visuals, patient videos and technical content that can be reorganized into a stronger Technology page.
01Review existing assets
02Reuse approved originals
03Improve the presentation
04Identify visual gaps
The Technology Page
Platform overview, components, how it works, artificial vision, motor recovery and intellectual property can be presented together.
A Note on Custom Graphics
If new graphics would materially improve the website, IBN will recommend them and provide pricing if you would like our team to develop the assets.
cortigent
Current Programs + Technology Legacy
The site will distinguish today's investigational programs from the predecessor experience that helped build the platform.
Clinical Progress and History
Position Argus II within Cortigent’s technology history.
Orion completed a six-year Early Feasibility Study in 2025 and remains Cortigent's lead investigational program. Argus II was discontinued in 2019 and should appear only as historical technology and clinical experience that helped provide a foundation for later systems.
- Orion presented as the lead current program
- Stroke Recovery System presented as a development program
- Argus II clearly labeled discontinued and no longer available
- Breakthrough Device status never confused with FDA approval
References: Cortigent's Argus II history and Vivani's six-year Orion study release.
Investor Relations Rebuild
Make Investor Relations a destination, not a collection of links.
The Investor Overview page should deliver the strongest version of Cortigent's investment story in one visit, then guide visitors to focused pages and automated archives.
Investor OverviewNasdaq: CRGT
Investment Proposition
A focused neurotechnology company advancing precision neurostimulation across sight and motor function.
Verified highlights, development progress and public-company information presented in a format investors can scan.
Company SnapshotWho Cortigent is today
Technology PlatformHow the system works
Development ProgramsOrion + Stroke Recovery
Investor AccessQuote, filings, news, contact
Delayed Quote + Stock Information
Automated SEC Filings
Automated Press Releases
Governance + IR Contact
1
Investor OverviewInvestment proposition, snapshot, platform, programs, approved highlights, latest news, filings and contacts.
2
Stock InformationDelayed quote at launch, with charts, detailed quote tools and other modules available.
3
SEC FilingsAutomated QuoteMedia archive with filters and individual filing URLs.
4
Press ReleasesAutomated Cortigent news archive rather than individually designed pages.
5
Events and PresentationsCorporate presentations, approved videos, conference materials and event information.
6
Governance, FAQs and ContactBoard and committee information, annual meetings, transfer agent, email alerts and investor contact.
Examples from Other Public Companies
Complex investor information can be clear, visual and memorable.
These are examples from another public company's website. They demonstrate the approach IBN recommends for investment highlights, development strategy, platform characteristics and program architecture.
Clinical & Development Progress
Approved milestones translated into a concise, scan-friendly investor summary.
The examples demonstrate presentation quality and hierarchy. Cortigent's final highlights, metrics, clinical statements, ownership information and regulatory language will use current approved support.
QuoteMedia Content Solutions
Automate the public-company information investors expect to remain current.
IBN recommends delayed stock quotes, press releases and SEC filings as the launch set. Cortigent can also choose charts, Detailed Quote Tab, IR alerts, historical pricing, financial summaries and many other QuoteMedia modules.
Delayed QuoteCurrent trading information styled within the Cortigent website.
Press ReleasesAutomated company-news archive and latest-release modules.
SEC FilingsAutomated filings archive with filters and direct document access.
Recommended Website Structure
A thoughtful navigation structure for investors, patients and scientific audiences.
Visitors should be able to understand Cortigent at a glance, then use focused pages and dropdowns to reach the level of scientific, clinical or investor detail they need.
Recommended primary navigation
HomeCompanyTechnologyProgramsClinical & ResearchInvestorsNewsContact
“Programs” is easier for broad audiences than using “Pipeline” as the primary navigation label. Technical page headings can still use “Product Development Programs” or “Development Pipeline” when appropriate. Sections and modules do not become menu items merely because they appear on a page.
Approximately 20 core pages
Dynamic press releases, SEC filings, events and documents are archive entries rather than individually designed custom pages.
20Recommended core architecture
Foundation and Company
01
HomePublic-company narrative, platform, programs, proof and latest investor information.
02
Company OverviewMission, company profile, post-merger structure and headquarters.
03
Leadership and BoardPost-closing executives and directors with approved biographies.
04
History and Technology LegacySecond Sight and Argus II presented as historical context, not current products.
Technology and Programs
05
Precision Neurostimulation TechnologyPlatform, components, how it works, applications and intellectual property.
06
Programs OverviewOne platform connected to Orion and Stroke Recovery.
07
Orion®Lead artificial-vision program, system explanation and approved development status.
08
Stroke Recovery SystemDevelopment-stage motor-recovery program and scientific rationale.
Clinical and Research
09
Orion Clinical DevelopmentSix-year EFS, approved results, investigators and next development path.
10
PublicationsScientific publications and research references.
11
Patient Stories and VideosApproved human impact content with clear current/legacy context.
12
Prospective StudiesJoin-study information, form, consent and privacy language.
Investors and Contact
13
Investor OverviewInvestment proposition, snapshot, platform, programs and latest updates.
14
Stock InformationQuoteMedia quote and approved market-data tools.
15
SEC FilingsAutomated archive for annual, quarterly and other filings.
16
Press ReleasesAutomated company-news archive.
17
Events and PresentationsPresentations, videos, conferences and corporate events.
18
Corporate Governance and Annual MeetingsGovernance and document archive.
19
Investor FAQs and ContactTransfer agent, IR details, alerts and inquiries.
20
ContactGeneral, patient, clinical and corporate inquiry paths.
Page Consolidation
More scientific and investor depth does not require an oversized website.
Modular design and dynamic content keep the architecture focused, maintainable and aligned with the project scope detailed in the formal proposal.
Precision Neurostimulation Technology
Includes the platform overview, implant, wireless receiver, wearable processing, how it works, artificial-vision application, motor-cortex application, platform characteristics and intellectual property on one substantial page.
Programs Overview
Provides the one-platform/two-program architecture and concise development status. Orion and the Stroke Recovery System retain focused pages for the details.
History and Technology Legacy
Second Sight and Argus II are presented as historical experience. Argus II is clearly labeled discontinued and is not shown within current development programs.
Orion Clinical Development
Approved study design, six-year results, investigators, regulatory status, publications and future development language work together rather than being scattered across multiple pages.
Investor Overview
Investment Highlights, Company Snapshot, Technology Platform, Development Programs, Clinical Progress, Latest Filings, Latest News, stock information, contact details and email alerts are modules within one page.
Governance and Annual Meetings
Board and committee information, charters, ethics materials, proxy statements, voting results and annual-meeting documents share one organized destination.
Patient Stories and Videos
Approved Orion, Argus II and educational video content can be organized with clear labels explaining whether material is current, investigational or historical.
Dynamic News and Document Archives
QuoteMedia press releases and SEC filings populate automated archives. Events, presentations and selected documents use reusable templates rather than an unlimited number of custom page designs.
Corrections, Cleanup and Migration
IBN will rebuild the foundation.
The project includes strategic editing, link cleanup, content reconciliation and efficient migration of useful technology, clinical and historical material into the new WordPress website.
Proposed corrections and reconciliation
1
Replace subsidiary-era positioningRemove Vivani-parent language and present Cortigent Holdings, Inc. as the post-merger Nasdaq-listed company.
2
Update leadership and governanceUse the final post-closing executive team, board, committees, governance documents and approved biographies.
3
Reconcile clinical-development languageReplace stale references to an ongoing Orion EFS or 36-month results with approved language reflecting the completed six-year study and current path.
4
Separate current programs from historyRemove Argus II from any current pipeline treatment and label it clearly as discontinued legacy technology.
5
Verify patent and metric figuresResolve differing public patent counts and use only current figures with an approved measurement date.
6
Correct metadata and utility issuesReplace generic page titles such as “General 1,” repair links, establish redirects and add privacy, cookie and medical/regulatory language for approval.
7
Plan legacy ClearOne handlingOrganize required historical filings, releases and any ongoing product-support destination without allowing the former AV business to obscure Cortigent's new identity.
Efficient content and system migration
IBN can reuse appropriate existing pages, technology explanations, media, videos, publications and historical materials while rebuilding the presentation and integrating the public-company systems.
1
Preferred accessCortigent provides administrator access to the current website, media library and relevant post-merger investor materials.
2
Content reconciliationIBN reviews the website against current filings, releases and approved internal guidance before rewriting.
3
QuoteMedia setupCortigent establishes the account; IBN integrates the agreed delayed quote, release and filing feeds.
4
Historical organizationCurrent Cortigent and required ClearOne records are organized into logical archives rather than individually designed pages.
Custom graphics: existing approved assets are included in the design process. Any original diagrams, illustrations, renderings or extensive image recreation will be recommended, quoted and approved separately before work begins.
QuoteMediaDelayed quote, SEC filings and press releases recommended for launch. View catalog.
accessiBeIf accessibility features are needed, IBN advises Cortigent to establish an account with accessiBe. IBN will implement it with no integration upcharge. Learn more.
Website Features and Benefits
A complete public-company website, not just a redesigned homepage.
The $10,000 base project includes the agreed content architecture, full content development, responsive development and the standard systems required to operate and expand the website.
Design and Content
- Thoughtfully organized core content architecture within the agreed scope
- Completely new layouts and a consistent interior-page theme
- IBN research, strategic organization and content writing
- Interactive tiles and animation elements where appropriate
- FlippingBook service for primary documents
- Thoughtful placement and treatment of approved Cortigent technology assets
Responsive Experience
- Mobile, tablet, laptop and desktop formatting
- Click-to-call functionality on smartphones
- Cross-browser compatibility for Edge, Firefox, Chrome and Safari
- Functional contact forms instead of exposed email addresses
- Facebook, X and LinkedIn buttons
WordPress Ownership
- WordPress content-management system
- Full website ownership and administrative access
- Dynamic archive templates for releases, filings, events and annual meetings
- Manual publishing workflow for Cortigent's team where content is not automated
- Expandable structure without an unlimited custom-page commitment
Search and Discovery
- Search-engine optimization across website pages
- Properly configured XML sitemap
- Automated SEO tools for URLs and new content
- Schema markup implementation and maintenance
- Properly configured llms.txt file that updates as content is added
Analytics and Conversion
- Google Analytics setup for traffic monitoring
- Investor email-alert signup forms in key locations
- Calls to action for investors, patients, clinicians and partners
- Transfer-agent and investor-contact information organized clearly
- Prospective-study and inquiry forms designed around useful next steps
Investor Content Systems
- QuoteMedia delayed quote, release and filing integrations
- Financial-results content organized within Investor Overview and filing archives
- Stock information and agreed QuoteMedia market tools
- Governance and annual-meeting document archives
- Approved videos, interviews, presentations and downloads
“Multiple plugins and third-party services may be required to provide the requested functionality. IBN carefully selects established tools but cannot guarantee that third-party plugins, QuoteMedia feeds, accessiBe or other external services will always operate flawlessly. Services may occasionally require replacement or reconfiguration as WordPress, PHP, browser and vendor technologies evolve. accessiBe implementation is not a substitute for legal advice or a formal accessibility conformance audit.”
Public-company context built into the process.
IBN understands how to organize investment highlights, technology content, filings and corporate communications into a stronger online presence.
75+Trusted brands designed for targeted reach to the investment public
600+Public and private companies represented across the IBN platform
DozensOf websites operated across IBN's own ecosystem
01
Website and communications experienceIBN has gained significant experience reviewing public-company sites, building client websites and providing strategic recommendations.
02
Investor-relations collaborationIBN regularly works alongside investor-relations and public-relations professionals and understands how the website supports those efforts.
03
Content organizationIBN can turn filings, releases, scientific material, clinical progress and approved presentations into a coherent, scannable corporate narrative.
04
Minimal burden on CortigentIBN will lead research, writing, organization, migration, design and development rather than waiting for Cortigent to produce every page.
Project Process
Complete the website on a testing server, approve it, then launch.
This project follows IBN's normal build-and-approval process rather than an accelerated soft-launch structure.
Formal Approval and Access
Approve the Qwilr proposal, provide the necessary access and answer the focused kickoff questions.
50% initial paymentResearch, Content and Build
IBN organizes public information, writes the website, develops the WordPress design and integrates approved systems.
IBN-led productionTesting-Server Completion
The agreed website is completed on IBN's testing server and made ready for Cortigent's final review and approval.
Final 50% paymentApproval and Launch
After all within-scope items are approved and final payment is received, IBN moves the completed website to the live domain.
Public launchProject Investment
Project investment at a glance.
The formal Qwilr proposal contains the official scope, pricing, payment terms and approval. The $10,000 base project covers the recommended core content architecture, agreed QuoteMedia integrations, forms and standard website functionality outlined in this strategy.
Payment Schedule
Project Kickoff50% | $5,000
Due upfront to begin research, content development, design and production.
Testing-Server Completion50% | $5,000
Due when the agreed website is completed on the testing server and ready for final approval.
Launch milestone: once all within-scope items are approved and final payment has been received, IBN will move the website from the testing server to the live domain.
Optional Upgrades
Available when Cortigent wants to expand beyond the base scope.
The following items are optional and billed separately when requested. They are not included in the base website project.
Additional custom pages beyond the approximately 20-page core architecture
Original custom medical, device or technology diagrams and illustrations
New 3D renderings, animation or extensive recreation of existing technical artwork
Additional QuoteMedia modules or custom configurations beyond the agreed launch set
AWeber, Mailchimp or another email-newsletter subscription
Premium WordPress plugins
Stock photography or licensed video
Extensive historical content migration beyond the agreed archive plan
Specialized functionality outside the agreed scope
QuoteMedia licensing/data charges and the optional accessiBe subscription would be paid directly by Cortigent. IBN's agreed integrations are included in the base development price.
Ongoing Support
Cortigent keeps full control after launch.
Cortigent will retain full administrative access and ownership. The internal team may make updates through WordPress, while IBN remains available for future design, content and functionality work.
Administrative Access
Cortigent retains control of the website, content and WordPress administration area.
Standard Hourly Rate
Future work requested from IBN will generally be billed at $80 per hour, depending on the skill level required.
Prepaid 10-Hour Block
Recommended when Cortigent expects recurring content updates, design refinements or other post-launch assistance.
IBN will carry the project.
Cortigent should not have to build the content plan, write every page or organize all historical and technical material before the redesign can move forward.
Provide necessary website and system access
Answer essential questions
Review the strategy and testing website
Identify anything that should not be used
Questions for Cortigent
A few focused decisions will help IBN finalize the build.
These can be answered efficiently during kickoff. IBN will continue using public information and its own research to minimize the burden on Cortigent's leadership.
Corporate, Clinical and Technology Decisions
- Please confirm the post-merger leadership, board, approved biographies and headshots.
- Should the website use specific projected dates for development milestones or describe the path without dates?
- Which patent figures and measurement date should the website use? Public materials currently contain differing counts.
- How prominently should Argus II appear within Cortigent's history?
- Should the Prospective Studies / Join Our Study List feature remain? If so, who receives submissions?
Investor Relations, QuoteMedia and Historical Records
- Which QuoteMedia modules should be included at launch? IBN recommends delayed quote, press releases and SEC filings at minimum.
- How should pre-merger ClearOne SEC filings, annual reports and press releases be organized? For instance, we could do within filtered historical archives or a separate legacy section.
- Should selected pre-merger Cortigent and Vivani releases remain available as historical Cortigent news?
- Who will provide final review and approval before publication?
Legacy Support, Accessibility, Hosting and Scope
- What is the post-merger plan for legacy ClearOne product warranty and technical support? Should clearone.com remain a standalone support destination, and should cortigent.com link to it?
- Does Cortigent plan to establish an accessiBe account for launch so IBN can implement it at no additional integration charge?
- What hosting and ongoing website-management arrangement does Cortigent prefer?
Recommended Next Step
Review the formal proposal when Cortigent is ready to move forward.
This strategy establishes the recommended direction for the new website. Cortigent can review and approve the official project scope, pricing and payment terms through IBN's Qwilr proposal. Once approved, IBN will request the necessary access and begin research, content, design and development.
The Qwilr page is the official approval document for this project.